Latest Report - Diabetic Retinopathy - Pipeline Review, H1 2014

287 views
240 views

Published on

Diabetic Retinopathy - Pipeline Review, H1 2014 @ http://www.researchmoz.us/diabetic-retinopathy-pipeline-review-h1-2014-report.html

The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Research team.

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
287
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Latest Report - Diabetic Retinopathy - Pipeline Review, H1 2014

  1. 1. Diabetic Retinopathy - Pipeline Review, H1 2014 Diabetic Retinopathy - Pipeline Review, H1 2014 Summary Global Markets Directs, Diabetic Retinopathy - Pipeline Review, H1 2014, provides an overview of the Diabetic Retinopathys therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Diabetic Retinopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Retinopathy and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Diabetic Retinopathy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diabetic Retinopathy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diabetic Retinopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Diabetic Retinopathy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diabetic Retinopathy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diabetic Retinopathy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Table Of Contents table Of Contents 2 list Of Tables 5 list Of Figures 6 introduction 7 global Markets Direct Report Coverage 7 diabetic Retinopathy Overview 8 therapeutics Development 9 pipeline Products For Diabetic Retinopathy - Overview 9 pipeline Products For Diabetic Retinopathy - Comparative Analysis 10 diabetic Retinopathy - Therapeutics Under Development By Companies 11 diabetic Retinopathy - Therapeutics Under Investigation By Universities/institutes 15 diabetic Retinopathy - Pipeline Products Glance 16 late Stage Products 16 clinical Stage Products 17 Diabetic Retinopathy - Pipeline Review, H1 2014
  2. 2. early Stage Products 18 unknown Stage Products 19 diabetic Retinopathy - Products Under Development By Companies 20 diabetic Retinopathy - Products Under Investigation By Universities/institutes 23 diabetic Retinopathy - Companies Involved In Therapeutics Development 24 antisense Therapeutics Limited 24 lpath, Inc. 25 biodiem Ltd 26 regenerx Biopharmaceuticals, Inc. 27 thrombogenics Nv 28 r-tech Ueno, Ltd. 29 paloma Pharmaceuticals, Inc. 30 acucela Inc. 31 protemix Corporation Limited 32 gene Signal International Sa 33 promedior, Inc. 34 inotek Pharmaceuticals Corporation 35 intercept Pharmaceuticals, Inc. 36 firststring Research, Inc. 37 resolvyx Pharmaceuticals, Inc 38 charlesson Llc. 39 stelic Institute & Co. 40 eyecyte, Inc. 41 vascular Pharmaceuticals, Inc. 42 protagonist Therapeutics Inc. 43 panoptica, Inc. 44 eyegene, Inc. 45 targazyme, Inc. 46 ampio Pharmaceuticals, Inc. 47 mingsight Pharmaceuticals 48 bionure Farma, S.l. 49 foresee Pharmaceuticals, Llc 50 biomar Microbial Technologies 51 ccrp Therapeutics Gmbh 52 diabetic Retinopathy - Therapeutics Assessment 53 assessment By Monotherapy Products 53 assessment By Target 54 assessment By Mechanism Of Action 58 assessment By Route Of Administration 61 assessment By Molecule Type 64 drug Profiles 67 dmi-5207 - Drug Profile 67 lt-1009 - Drug Profile 68 ocriplasmin - Drug Profile 72 rgn-259 - Drug Profile 75 akb-9778 - Drug Profile 77 gc-811007 - Drug Profile 79 atl-1103 - Drug Profile 81 dg-3173 - Drug Profile 82 emixustat - Drug Profile 84 aganirsen - Drug Profile 86 gly-230 - Drug Profile 88 eg-mirotin - Drug Profile 90 gs-102 - Drug Profile 92 parp Inhibitors - Drug Profile 93 dt-23552 - Drug Profile 94 rx-20001 - Drug Profile 95 p-529 - Drug Profile 96 int-767 - Drug Profile 98 mtp-131 - Drug Profile 100 bdm-e - Drug Profile 102 rtu-007 - Drug Profile 104 a-717 - Drug Profile 105 ms-553 - Drug Profile 106 pan-90806 - Drug Profile 107 fp-002 - Drug Profile 109 drug For Age-related Macular Degeneration And Diabetic Retinopathy - Drug Profile 110 stromal Cell Therapy For Diabetic Complications - Drug Profile 111 Diabetic Retinopathy - Pipeline Review, H1 2014
  3. 3. vpi-2690-b - Drug Profile 112 interleukin-6 Disulfide Rich Peptides Antagonist Program - Drug Profile 113 small Molecule For Diabetic Neuropathy And Retinopathy - Drug Profile 114 asc-101 - Drug Profile 115 v-1932 - Drug Profile 117 ec-301 Program - Drug Profile 118 c16y Peptide - Drug Profile 119 therapy For End-organ Damage - Drug Profile 120 drug To Activate Egf-like-domain Multiple 7 For Oncology And Diabetic Retinopathy - Drug Profile 121 adenomatosis Polyposis Coli Down-regulated 1 - Drug Profile 122 autologous Stem Cell Therapy For Diabetic Retinopathy - Drug Profile 123 stnm-1510 - Drug Profile 124 clt-010 - Drug Profile 125 ib-09a0133 - Drug Profile 126 clt-01007 - Drug Profile 127 clt-01001 - Drug Profile 128 clt-01012 - Drug Profile 129 neuregulins - Drug Profile 130 bn-201 - Drug Profile 131 ec-200 Program - Drug Profile 132 bn-204 - Drug Profile 133 bn-206 - Drug Profile 134 rgn-259 - Drug Profile 135 prm-167 - Drug Profile 137 bn-205 - Drug Profile 139 diabetic Retinopathy - Recent Pipeline Updates 140 diabetic Retinopathy - Dormant Projects 166 diabetic Retinopathy - Discontinued Products 167 diabetic Retinopathy - Product Development Milestones 168 featured News & Press Releases 168 appendix 178 methodology 178 coverage 178 secondary Research 178 primary Research 178 expert Panel Validation 178 contact Us 179 disclaimer 179 ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Website: http://www.researchmoz.us/ Diabetic Retinopathy - Pipeline Review, H1 2014

×